Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts rate Pharming a "Moderate Buy" — five brokerages cover the stock (three buy, two hold) with an average 12‑month price target of $38.33 and recent initiations/upgrades from Canaccord, Oppenheimer, HC Wainwright, Zacks and Weiss Ratings.
• PHAR trades near $16.39 (12‑month range $8.60–$21.34) with a $1.16B market cap, but reported a quarterly earnings miss (EPS $0.07 vs. $0.15 est.) and revenue of $106.5M vs. $111.8M expected, and shows an unusually high reported PE of 1,639.
• Pharming is a clinical‑stage biotech whose lead product, RUCONEST, is approved for hereditary angioedema and is built on a transgenic protein‑production platform; institutional ownership is very low (~0.03%) despite some recent small investor acquisitions.

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $38.3333.

PHAR has been the topic of a number of recent analyst reports. Canaccord Genuity Group initiated coverage on shares of Pharming Group in a report on Friday, April 10th. They set a "buy" rating and a $37.00 price target on the stock. Oppenheimer restated an "outperform" rating and set a $41.00 price target (down from $42.00) on shares of Pharming Group in a report on Friday, March 13th. Zacks Research upgraded shares of Pharming Group from a "strong sell" rating to a "hold" rating in a report on Friday, April 10th. HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, March 24th. Finally, Weiss Ratings upgraded shares of Pharming Group from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, April 27th.

Pharming Group Stock Down 3.5%

PHAR stock opened at $16.39 on Tuesday. Pharming Group has a 12 month low of $8.60 and a 12 month high of $21.34. The firm has a market cap of $1.16 billion, a PE ratio of 1,639.00 and a beta of 0.04. The firm has a 50 day simple moving average of $16.39 and a 200 day simple moving average of $16.55. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.59 and a quick ratio of 2.03.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.08). Pharming Group had a net margin of 0.71% and a return on equity of 1.08%. The firm had revenue of $106.50 million for the quarter, compared to analyst estimates of $111.76 million. Equities research analysts forecast that Pharming Group will post 0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A number of large investors have recently made changes to their positions in the company. NewEdge Advisors LLC raised its holdings in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company's stock valued at $510,000 after acquiring an additional 28,615 shares during the period. Millennium Management LLC acquired a new position in Pharming Group in the fourth quarter worth approximately $360,000. SmartHarvest Portfolios LLC bought a new position in Pharming Group during the fourth quarter valued at approximately $224,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in Pharming Group in the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.